Top

Cancer Cell International

Published in:

01-12-2022 | Breast Cancer | Primary research

Microarray analysis of breast cancer gene expression profiling in response to 2-deoxyglucose, metformin, and glucose starvation

Authors: Rita Aoun, Christopher El Hadi, Roula Tahtouh, Rita El Habre, George Hilal

Published in: Cancer Cell International | Issue 1/2022

Abstract

Background

Breast cancer (BC) is the most frequently diagnosed cancer in women. Altering glucose metabolism and its effects on cancer progression and treatment resistance is an emerging interest in BC research. For instance, combining chemotherapy with glucose-lowering drugs (2-deoxyglucose (2-DG), metformin (MET)) or glucose starvation (GS) has shown better outcomes than with chemotherapy alone. However, the genes and molecular mechanisms that govern the action of these glucose deprivation conditions have not been fully elucidated. Here, we investigated the differentially expressed genes in MCF-7 and MDA-MB-231 BC cell lines upon treatment with glucose-lowering drugs (2-DG, MET) and GS using microarray analysis to study the difference in biological functions between the glucose challenges and their effect on the vulnerability of BC cells.

Methods

MDA-MB-231 and MCF-7 cells were treated with 20 mM MET or 4 mM 2-DG for 48 h. GS was performed by gradually decreasing the glucose concentration in the culture medium to 0 g/L, in which the cells remained with fetal bovine serum for one week. Expression profiling was carried out using Affymetrix Human Clariom S microarrays. Differentially expressed genes were obtained from the Transcriptome Analysis Console and enriched using DAVID and R packages.

Results

Our results showed that MDA-MB-231 cells were more responsive to glucose deprivation than MCF-7 cells. Endoplasmic reticulum stress response and cell cycle inhibition were detected after all three glucose deprivations in MDA-MB-231 cells and only under the metformin and GS conditions in MCF-7 cells. Induction of apoptosis and inhibition of DNA replication were observed with all three treatments in MDA-MB-231 cells and metformin-treated MCF-7 cells. Upregulation of cellular response to reactive oxygen species and inhibition of DNA repair mechanisms resulted after metformin and GS administration in MDA-MB-231 cell lines and metformin-treated MCF-7 cells. Autophagy was induced after 2-DG treatment in MDA-MB-231 cells and after metformin in MCF-7 cells. Finally, inhibition of DNA methylation were observed only with GS in MDA-MB-231 cells.

Conclusion

The procedure used to process cancer cells and analyze their expression data distinguishes our study from others. GS had the greatest effect on breast cancer cells compared to 2-DG and MET. Combining MET and GS could restrain both cell lines, making them more vulnerable to conventional chemotherapy.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Griguolo G, Dieci MV, Miglietta F, Guarneri V, Conte P. Olaparib for advanced breast cancer. Future Oncol. 2020;16:717–32. https://doi.org/10.2217/fon-2019-0689.CrossRefPubMed

Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84: 106535. https://doi.org/10.1016/j.intimp.2020.106535.CrossRefPubMed

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67. https://doi.org/10.1172/JCI45014.CrossRefPubMedPubMedCentral

Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020;50:225–9. https://doi.org/10.1093/jjco/hyz213.CrossRefPubMed

Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288–300. https://doi.org/10.1001/jama.2018.19323.CrossRefPubMed

Yin L, Duan J-J, Bian X-W, Yu S-C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61. https://doi.org/10.1186/s13058-020-01296-5.CrossRefPubMedPubMedCentral

Zhang H-H, Guo X-L. Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol. 2016;78:13–26. https://doi.org/10.1007/s00280-016-3037-3.CrossRefPubMed

Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.CrossRefPubMed

10.

Varghese E, Samuel SM, Líšková A, Samec M, Kubatka P, Büsselberg D. Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12082252.CrossRef

11.

Peng M, Darko KO, Tao T, Huang Y, Su Q, He C, et al. Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. Cancer Treat Rev. 2017;54:24–33. https://doi.org/10.1016/j.ctrv.2017.01.005.CrossRefPubMed

12.

De A, Kuppusamy G. Metformin in breast cancer: preclinical and clinical evidence. Curr Probl Cancer. 2020;44: 100488. https://doi.org/10.1016/j.currproblcancer.2019.06.003.CrossRefPubMed

13.

Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;16:1695–700. https://doi.org/10.1158/1078-0432.CCR-09-1805.CrossRefPubMedPubMedCentral

14.

Roshan MH, Shing YK, Pace NP. Metformin as an adjuvant in breast cancer treatment. SAGE Open Med. 2019. https://doi.org/10.1177/2050312119865114.CrossRefPubMedPubMedCentral

15.

Ciavardelli D, Rossi C, Barcaroli D, Volpe S, Consalvo A, Zucchelli M, et al. Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis. 2014;5:e1336. https://doi.org/10.1038/cddis.2014.285.CrossRefPubMedPubMedCentral

16.

Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 2014;355:176–83. https://doi.org/10.1016/j.canlet.2014.09.003.CrossRefPubMed

17.

Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther. 2007;6:3049–58. https://doi.org/10.1158/1535-7163.MCT-07-0310.CrossRefPubMed

18.

Reckzeh ES, Waldmann H. Small-Molecule Inhibition of Glucose Transporters GLUT-1–4. ChemBioChem. 2020;21:45–52. https://doi.org/10.1002/cbic.201900544.CrossRefPubMed

19.

Kim SW, Cha M-J, Lee S-K, Song B-W, Jin X, Lee JM, et al. Curcumin Treatment in Combination with Glucose Restriction Inhibits Intracellular Alkalinization and Tumor Growth in Hepatoma Cells. Int J Mol Sci 2019;20. https://doi.org/10.3390/ijms20102375.

20.

Meynet O, Ricci J-E. Caloric restriction and cancer: molecular mechanisms and clinical implications. Trends Mol Med. 2014;20:419–27. https://doi.org/10.1016/j.molmed.2014.05.001.CrossRefPubMed

21.

Seyfried TN, Flores RE, Poff AM, D’Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35:515–27. https://doi.org/10.1093/carcin/bgt480.CrossRefPubMed

22.

Schroeder U, Himpe B, Pries R, Vonthein R, Nitsch S, Wollenberg B. Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. Nutr Cancer. 2013;65:843–9. https://doi.org/10.1080/01635581.2013.804579.CrossRefPubMed

23.

Saito S, Furuno A, Sakurai J, Sakamoto A, Park H-R, Shin-Ya K, et al. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res. 2009;69:4225–34. https://doi.org/10.1158/0008-5472.CAN-08-2689.CrossRefPubMed

24.

Shioda T, Chesnes J, Coser KR, Zou L, Hur J, Dean KL, et al. Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens. Proc Natl Acad Sci USA. 2006;103:12033–8. https://doi.org/10.1073/pnas.0605341103.CrossRefPubMedPubMedCentral

25.

Allain C, Angenard G, Clément B, Coulouarn C. Integrative genomic analysis identifies the core transcriptional hallmarks of human hepatocellular carcinoma. Cancer Res. 2016;76:6374–81. https://doi.org/10.1158/0008-5472.CAN-16-1559.CrossRefPubMedPubMedCentral

26.

Yu S-L, Lee DC, Baek SW, Cho DY, Choi JG, Kang J. Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma. Cancer Manag Res. 2018;10:6379–89. https://doi.org/10.2147/CMAR.S174966.CrossRefPubMedPubMedCentral

27.

Mo W, Liu Q, Lin C-J, Dai H, Peng Y, Liang Y, et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res. 2016;22:1699–712.CrossRefPubMed

28.

Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 2015;34:1349–70.CrossRefPubMedPubMedCentral

29.

Larsson O, Morita M, Topisirovic I, Alain T, Blouin M-J, Pollak M, et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci USA. 2012;109:8977–82. https://doi.org/10.1073/pnas.1201689109.CrossRefPubMedPubMedCentral

30.

Asiedu MK, Barron M, Aubry MC, Wigle DA. Patient- and cell type-specific heterogeneity of metformin response. Basic Clin Pharmacol Toxicol. 2018;122:214–22. https://doi.org/10.1111/bcpt.12898.CrossRefPubMed

31.

David-West G, Ernlund A, Gadi A, Schneider RJ. mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs. Oncotarget. 2018;9:33064–76.CrossRefPubMedPubMedCentral

32.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716–35. https://doi.org/10.1158/2159-8290.CD-16-0441.CrossRefPubMedPubMedCentral

33.

Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, et al. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia. 2013;27:1677–87. https://doi.org/10.1038/leu.2013.28.CrossRefPubMed

34.

Zhan T, Ambrosi G, Wandmacher AM, Rauscher B, Betge J, Rindtorff N, et al. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer. Nat Commun. 2019;10:2197. https://doi.org/10.1038/s41467-019-09898-0.CrossRefPubMedPubMedCentral

35.

Caffa I, D’Agostino V, Damonte P, Soncini D, Cea M, Monacelli F, et al. Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. Oncotarget. 2015;6:11820–32.CrossRefPubMedPubMedCentral

36.

Müller D, Shin S, de GoulletRugy T, Samain R, Baer R, Strehaiano M, et al. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. JCI Insight. 2019;4:121951.CrossRefPubMed

37.

Transcriptome Analysis Console (TAC) Software - LB n.d. //www.thermofisher.com/sa/en/home/life-science/microarray-analysis/microarray-analysis-instruments-software-services/microarray-analysis-software/affymetrix-transcriptome-analysis-console-software.html. Accessed 17 Sept 2021.

38.

Venny 2.1.0 n.d. https://bioinfogp.cnb.csic.es/tools/venny/. Accessed 17 Sept 2021.

39.

Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. https://doi.org/10.1038/nprot.2008.211.CrossRef

40.

R: The R Project for Statistical Computing n.d. https://www.r-project.org/. Accessed 17 Sept 2021.

41.

Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. PNAS. 2001;98:5116–21. https://doi.org/10.1073/pnas.091062498.CrossRefPubMedPubMedCentral

42.

Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. gplots: Various R Programming Tools for Plotting Data. 2020.

43.

Gao C-H, Yu G, Cai P. ggVennDiagram: an intuitive, easy-to-use, and highly customizable R Package to generate venn diagram. Front Genet. 2021;12:706907. https://doi.org/10.3389/fgene.2021.706907.CrossRefPubMedPubMedCentral

44.

Pagès H, Carlson M, Falcon S, Li N. AnnotationDbi: Manipulation of SQLite-based annotations in Bioconductor. Bioconductor version: Release (3.13); 2021. https://doi.org/10.18129/B9.bioc.AnnotationDbi.

45.

Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–7. https://doi.org/10.1089/omi.2011.0118.CrossRefPubMedPubMedCentral

46.

Yu G, He Q-Y. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2016;12:477–9. https://doi.org/10.1039/c5mb00663e.CrossRefPubMed

47.

Gu Z, Hübschmann D. simplifyEnrichment: an R/Bioconductor package for clustering and visualizing functional enrichment results. 2021. https://doi.org/10.1101/2020.10.27.312116.

48.

Wilke CO. cowplot: Streamlined Plot Theme and Plot Annotations for “ggplot2.” 2020.

49.

Wickham H, François R, Henry L, Müller K, RStudio. dplyr: A Grammar of Data Manipulation. 2021.

50.

ggplot2: elegant graphics for data analysis 2016 - Google Search n.d. https://www.google.com/search?q=ggplot2%3A+elegant+graphics+for+data+analysis+2016&ei=Y-tEYenpGoqlUoCPhdAC&oq=H.+Wickham.+ggplot2%3A+Elegant+Graphics+for+Data+Analysis.+Springer-Verlag+New+York%2C+2016.&gs_lcp=Cgdnd3Mtd2l6EAEYATIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwA0oECEEYAFAAWABg__8CaAFwAngAgAEAiAEAkgEAmAEAyAEIwAEB&sclient=gws-wiz .Accessed 17 Sept 2021.

51.

Feng X, Shi Y, Xie L, Zhang K, Wang X, Liu Q, et al. 2-deoxy-D-glucose augments photodynamic therapy induced mitochondrial caspase-independent apoptosis and energy-mediated autophagy. Lasers Surg Med. 2019;51:352–62. https://doi.org/10.1002/lsm.23020.CrossRefPubMed

52.

Xi H, Barredo JC, Merchan JR, Lampidis TJ. Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy. Biochem Pharmacol. 2013;85:1463–77. https://doi.org/10.1016/j.bcp.2013.02.037.CrossRefPubMed

53.

Ronco AL, Martínez-López W, Mendoza B, Calderón JM. Epidemiologic evidence for association between a high dietary acid load and the breast cancer risk. Sci Med J. 2021;3:166–76.

54.

Cechowska-Pasko M, Krętowski R, Bańkowski E. Glucose deficiency reduces collagen synthesis in breast cancer MCF7 cells. Cell Biol Int. 2011;35:141–5. https://doi.org/10.1042/CBI20090383.CrossRefPubMed

55.

Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods. 2005;35:373–81. https://doi.org/10.1016/j.ymeth.2004.10.010.CrossRefPubMed

56.

Zordoky BNM, Bark D, Soltys CL, Sung MM, Dyck JRB. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta. 2014;1840:1943–57. https://doi.org/10.1016/j.bbagen.2014.01.023.CrossRefPubMed

57.

Gao Z-Y, Liu Z, Bi M-H, Zhang J-J, Han Z-Q, Han X, et al. Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Exp Ther Med. 2016;11:1700–6. https://doi.org/10.3892/etm.2016.3143.CrossRefPubMedPubMedCentral

58.

Marinello PC, da Silva TNX, Panis C, Neves AF, Machado KL, Borges FH, et al. Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor β1 induction. Tumour Biol. 2016;37:5337–46. https://doi.org/10.1007/s13277-015-4395-x.CrossRefPubMed

59.

Raut GK, Chakrabarti M, Pamarthy D, Bhadra MP. Glucose starvation-induced oxidative stress causes mitochondrial dysfunction and apoptosis via Prohibitin 1 upregulation in human breast cancer cells. Free Radic Biol Med. 2019;145:428–41. https://doi.org/10.1016/j.freeradbiomed.2019.09.020.CrossRefPubMed

60.

Marinello PC, Panis C, Silva TNX, Binato R, Abdelhay E, Rodrigues JA, et al. Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis. Pathol Res Pract. 2020;216: 153135. https://doi.org/10.1016/j.prp.2020.153135.CrossRefPubMed

61.

Queiroz EAIF, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS ONE. 2014;9:e98207. https://doi.org/10.1371/journal.pone.0098207.CrossRefPubMedPubMedCentral

62.

Tanaka Y, Konishi A, Obinata H, Tsuneoka M. Metformin activates KDM2A to reduce rRNA transcription and cell proliferation by dual regulation of AMPK activity and intracellular succinate level. Sci Rep. 2019;9:18694. https://doi.org/10.1038/s41598-019-55075-0.CrossRefPubMedPubMedCentral

63.

Sharma P, Kumar S. Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD). Cell Oncol (Dordr). 2018;41:637–50. https://doi.org/10.1007/s13402-018-0398-0.CrossRef

64.

Dias Lopes NM, Marinello PC, Sanches LJ, da Silva Brito WA, Lovo-Martins MI, Pinge-Filho P, et al. Patterns of cell death induced by metformin in human MCF-7 breast cancer cells. Pathol Res Pract. 2020;216:153199. https://doi.org/10.1016/j.prp.2020.153199.CrossRefPubMed

65.

Rizvi F, Alam M, Asad F. Promising role of Metformin in reducing the viability of breast cancerous cells. Pak J Pharm Sci. 2020;33:543–9.PubMed

66.

Siddiqui A, Ceppi P. A non-proliferative role of pyrimidine metabolism in cancer. Mol Metab. 2020;35: 100962. https://doi.org/10.1016/j.molmet.2020.02.005.CrossRefPubMedPubMedCentral

67.

Hook SS, Lin JJ, Dutta A. Mechanisms to control rereplication and implications for cancer. Curr Opin Cell Biol. 2007;19:663–71. https://doi.org/10.1016/j.ceb.2007.10.007.CrossRefPubMedPubMedCentral

68.

Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. 2014;16:746–52. https://doi.org/10.1007/s12094-013-1144-8.CrossRefPubMed

69.

Özdemİr A, Ark M. A novel ROCK inhibitor: off-target effects of metformin. Turk J Biol. 2021;45:35–45. https://doi.org/10.3906/biy-2004-12.CrossRefPubMedPubMedCentral

70.

Tądel K, Wiatrak B, Bodetko D, Barg E. Metformin and proliferation of cancer cell lines. Pediatr Endocrinol Diabetes Metab. 2020;26:159–66. https://doi.org/10.5114/pedm.2020.98713.CrossRefPubMed

71.

Krętowski R, Stypułkowska A, Cechowska-Pasko M. Low-glucose medium induces ORP150 expression and exerts inhibitory effect on apoptosis and senescence of human breast MCF7 cells. Acta Biochim Pol. 2013;60:167–73.CrossRefPubMed

72.

Sedoris KC, Thomas SD, Miller DM. c-myc promoter binding protein regulates the cellular response to an altered glucose concentration. Biochemistry. 2007;46:8659–68. https://doi.org/10.1021/bi7003558.CrossRefPubMed

73.

Krętowski R, Borzym-Kluczyk M, Stypułkowska A, Brańska-Januszewska J, Ostrowska H, Cechowska-Pasko M. Low glucose dependent decrease of apoptosis and induction of autophagy in breast cancer MCF-7 cells. Mol Cell Biochem. 2016;417:35–47. https://doi.org/10.1007/s11010-016-2711-4.CrossRefPubMedPubMedCentral

74.

Belkacemi L, Lam E, Caldwell JD, Siemens DR, Graham CH. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation. Exp Cell Res. 2006;312:1685–92. https://doi.org/10.1016/j.yexcr.2006.02.004.CrossRefPubMed

75.

Lee JO, Kang MJ, Byun WS, Kim SA, Seo IH, Han JA, et al. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51. Breast Cancer Res. 2019;21:115. https://doi.org/10.1186/s13058-019-1204-2.CrossRefPubMedPubMedCentral

76.

Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9:616–27. https://doi.org/10.1038/nrm2450.CrossRefPubMedPubMedCentral

77.

Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol. 2019;12:43. https://doi.org/10.1186/s13045-019-0733-6.CrossRefPubMedPubMedCentral

78.

Gatseva A, Sin YY, Brezzo G, Van Agtmael T. Basement membrane collagens and disease mechanisms. Essays Biochem. 2019;63:297–312. https://doi.org/10.1042/EBC20180071.CrossRefPubMedPubMedCentral

79.

Ren J, Smid M, Iaria J, Salvatori DCF, van Dam H, Zhu HJ, et al. Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression. Breast Cancer Res. 2019;21:109. https://doi.org/10.1186/s13058-019-1194-0.CrossRefPubMedPubMedCentral

80.

Jariyal H, Gupta C, Srivastava A. Hyaluronic acid induction on breast cancer stem cells unfolds subtype specific variations in stemness and epithelial-to-mesenchymal transition. Int J Biol Macromol. 2020;160:1078–89. https://doi.org/10.1016/j.ijbiomac.2020.05.236.CrossRefPubMed

81.

Janiszewska M, Primi MC, Izard T. Cell adhesion in cancer: beyond the migration of single cells. J Biol Chem. 2020;295:2495–505. https://doi.org/10.1074/jbc.REV119.007759.CrossRefPubMedPubMedCentral

82.

Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, et al. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010;103:249–55. https://doi.org/10.1038/sj.bjc.6605735.CrossRefPubMedPubMedCentral

83.

Abdoul-Azize S, Buquet C, Li H, Picquenot J-M, Vannier J-P. Integration of Ca2⁺ signaling regulates the breast tumor cell response to simvastatin and doxorubicin. Oncogene. 2018;37:4979–93. https://doi.org/10.1038/s41388-018-0329-6.CrossRefPubMed

84.

Kumar N, Prasad P, Jash E, Jayasundar S, Singh I, Alam N, et al. cAMP regulated EPAC1 supports microvascular density, angiogenic and metastatic properties in a model of triple negative breast cancer. Carcinogenesis. 2018;39:1245–53. https://doi.org/10.1093/carcin/bgy090.CrossRefPubMedPubMedCentral

85.

Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743–50. https://doi.org/10.1101/gr.165985.113.CrossRefPubMedPubMedCentral

86.

Agrawal S, Kishore MC. MHC class I gene expression and regulation. J Hematother Stem Cell Res. 2000;9:795–812. https://doi.org/10.1089/152581600750062237.CrossRefPubMed

87.

Lee HJ, Song IH, Park IA, Heo S-H, Kim Y-A, Ahn J-H, et al. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget. 2016;7:30119–32.CrossRefPubMedPubMedCentral

Title: Microarray analysis of breast cancer gene expression profiling in response to 2-deoxyglucose, metformin, and glucose starvation
Authors: Rita Aoun
Christopher El Hadi
Roula Tahtouh
Rita El Habre
George Hilal
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Breast Cancer
Metformin
Breast Cancer
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-022-02542-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Evaluation of X-ray and carbon-ion beam irradiation with chemotherapy for the treatment of cervical adenocarcinoma cells in 2D and 3D cultures

Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-β signaling by recruiting Rab5c

Integrated assessment of the clinical and biological value of ferroptosis-related genes in multiple myeloma

Sestrin2 reduces cancer stemness via Wnt/β-catenin signaling in colorectal cancer

RBM10 regulates alternative splicing of lncRNA Neat1 to inhibit the invasion and metastasis of NSCLC

Correction to: Identification and validation of the high expression of pseudogene TCAM1P in cervical cancer via integrated bioinformatics analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer